Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	176	191	199	413	264	133
Market Cap Growth	9.33%	-4.09%	-51.84%	56.44%	98.01%	15.01%
Enterprise Value	136	158	145	357	226	84
PE Ratio	-	-8.88	-7.57	-9.60	-12.78	-11.39
PS Ratio	21.99	21.32	13.53	95.13	144.57	37.93
PB Ratio	2.43	3.01	2.71	4.48	2.74	1.18
P/FCF Ratio	-11.81	-6.52	307.85	-17.28	-13.34	-4.13
P/OCF Ratio	-12.08	-6.68	187.79	-17.53	-13.36	-4.17
EV/Sales Ratio	16.95	17.69	9.85	82.33	123.62	23.94
EV/EBITDA Ratio	-10.39	-7.00	-5.79	-8.48	-11.41	-5.26
EV/EBIT Ratio	-10.09	-6.79	-5.63	-8.31	-10.31	-4.40
EV/FCF Ratio	-10.10	-5.41	224.29	-14.95	-11.40	-2.60
Debt / Equity Ratio	0.04	0.05	0.05	0.03	0.03	0.05
Debt / EBITDA Ratio	-0.14	-0.13	-0.16	-0.07	-0.17	-0.32
Debt / FCF Ratio	-0.14	-0.10	6.03	-0.12	-0.17	-0.16
Quick Ratio	2.59	2.02	3.06	2.32	5.35	8.42
Current Ratio	2.71	2.14	3.16	2.37	5.66	8.86
Asset Turnover	0.08	0.08	0.11	0.03	0.02	0.02
Return on Equity (ROE)	-34.20%	-31.30%	-32.70%	-37.80%	-21.00%	-8.90%
Return on Assets (ROA)	-22.10%	-19.90%	-19.60%	-30.30%	-18.70%	-7.90%
Return on Capital (ROIC)	-32.72%	-37.26%	-29.16%	-51.79%	-26.58%	-32.91%
Earnings Yield	-13.44%	-11.26%	-13.21%	-10.42%	-7.82%	-8.78%
FCF Yield	-13.43%	-15.33%	0.32%	-5.79%	-7.50%	-24.23%
Buyback Yield / Dilution	-7.51%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%
Total Shareholder Return	-7.51%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).